Solicitation #: 15DDHQ21Q00000059
“The Drug Enforcement Administration’s (DEA) Diversion Control Division (DC), Drug and Chemical Evaluation Section is responsible for evaluating drugs and chemicals to determine whether these substances have abuse potential. These evaluations are used by DEA to support its domestic scheduling activities.”
“Recently, numerous designer substances with benzodiazepine-like activity have been abused in the United States and pose a significant risk to the public safety. Law enforcement and forensic laboratory databases have reported increased encounters of designer benzodiazepine substances … Due to the immediate public health threat associated with these designer benzodiazepine substances, several of them have been placed under international control. In order to place designer benzodiazepine substances under national permanent control, pharmacological data is required.
Anxiolysis is a pharmacological property that is associated with benzodiazepine drugs. The anxiolytic effects associated with benzodiazepines and related drugs have been reported to lead to abuse of this drug class. As such, DEA would like the vendor to assess the anxiolytic properties of the selected designer benzodiazepines in an in vivo pharmacological assay. Due to the time-sensitivity of this work, DEA is requesting that the pharmacological studies be initiated and completed in an expedient manner.”
Due date: 01 July 2021, 10:00 a.m. EDT